CBS 2019
CBSMD教育中心
中 文

Transcatheter Aortic Valve Replacement

Abstract

Recommended Article

Temporal Trends, Characteristics, and Outcomes of Infective Endocarditis After Transcatheter Aortic Valve Replacement Ambulatory Electrocardiogram Monitoring in Patients Undergoing Transcatheter Aortic Valve Replacement: JACC State-of-the-Art Review Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement: REFLECT II Health Status After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR: Results of the OVAL Study From organic and inorganic phosphates to valvular and vascular calcifications The Year in Cardiovascular Medicine 2020: Valvular Heart Disease: Discussing the Year in Cardiovascular Medicine for 2020 in the field of valvular heart disease is Professor Helmut Baumgartner and Dr Javier Bermejo. Mark Nicholls reports

EditorialMay 2, 2019

JOURNAL:N Engl J Med. Article Link

Informed Shared Decisions for Patients with Aortic Stenosis

CM Otto. Keywords: symptomatic aortic stenosis; TAVR; SAVR;

First 100 Words


Valve replacement is the only effective treatment for adults with severe, symptomatic aortic stenosis. The ideal prosthetic valve would be associated with minimal risk and discomfort at implantation, would have hemodynamics similar to those of a normal valve, would not require anticoagulation, and would be durable for the patient’s lifetime. We are moving closer to this goal, as evidenced by sequential randomized clinical trials of transcatheter aortic-valve replacement (TAVR), initially in patients at prohibitive or high estimated risk for death with surgical aortic-valve replacement, then in patients at intermediate risk, and now — in the trials by Mack et al.